ClinicalTrials.gg
RecruitingNCT05560958BIO|COLLECT-EPUpdated Sep 8, 2026

Post-market Clinical Follow-up Data Collection From Procedures With BIOTRONIK EP Products

An observational study in Cardiac Arrhythmia, sponsored by Biotronik SE & Co. KG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Biotronik SE & Co. KG · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
280
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Arrhythmias, Cardiac by Biotronik SE & Co. KG — 3 open to participants now, 4 under way, none of them phase 3. Arrhythmias, Cardiac · Biotronik SE & Co. KG.

Started
2023
the only one that year
Observational
3 of 12
1 open now
Registered
9th of 12
by date

Among the 12 studies in Arrhythmias, Cardiac by Biotronik SE & Co. KG, this one is the only one that started in 2023, is one of 3 observational ones, and was the 9th registered.

Arrhythmias, Cardiac

1,052 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.

Browse Arrhythmias, Cardiac studies →

Open to participants now

3 of the 12 studies in Arrhythmias, Cardiac by Biotronik SE & Co. KG are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 167 Arrhythmias, Cardiac studies recruiting now, 119 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arrhythmias, Cardiac by Biotronik SE & Co. KG, or all of them as a file.
02

Study summary

This data collection is designed to provide evidence for the safety, performance, and clinical benefit of BIOTRONIK's EP products. Additionally, residual risks will be monitored and newly emerging risks identified.

Read the detailed description

In this study, data from routine care will be collected and evaluated to support regulatory post-market clinical follow-up demands under MDR as well as maintenance of the regulatory approval of the BIOTRONIK's EP product portfolio in the CE region. This is a prospective, observational, multi-center, international, open-label, non-randomized study that aims to provide evidence for the clinical safety, performance, and clinical benefit of BIOTRONIK's EP products. The patients participating in the study either receive a diagnostic or therapeutic catheter intervention, which are indicated for temporary transvenous application in patients with cardiac arrhythmias. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.

03

Conditions studied

  • Cardiac Arrhythmia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients indicated for diagnosis and treatment of intracardiac arrhythmias in an EP lab environment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Indication for diagnostic or therapeutic EP intervention
  • EP intervention is planned to involve the use of BIOTRONIK EP products from at least 2 of the 3 following categories:

    • BIOTRONIK catheter (AlCath, ViaCath, MultiCath, Khelix)
    • BIOTRONIK external device (Qubic Stim, Qubic RF, Qiona)
    • BIOTRONIK transseptal sheath (Senovo Bi-Flex)
  • BIOTRONIK EP product is planned to be used within its intended purpose
  • Ability to understand the nature of the study
  • Willingness to provide written
  • Ability and willingness to perform all follow-up visits at the study site

Exclusion criteria

Exclusion Criteria:

  • Age less than 18 years
  • Pregnant or breastfeeding
  • Prior participation in this study with performed EP procedure
  • Participation in an interventional clinical investigation in parallel to the BIO\|COLLECT.EP study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
280 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Interventions

  • DeviceBIOTRONIK EP catheters (AlCath, MultiCath, ViaCath), external devices (Qubic RF, Qubic Stim, Qiona) and transseptal sheaths (Senovo bi-flex)

    Ablations and diagnostic catheters are indicated for temporary transvenous application in patients with cardiac arrhythmias during electrophysiology study (EPS) or catheter ablation interventions. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.

06

What researchers measure

Primary outcomes

  1. Rate of Device deficiencies

    Device deficiencies for each investigational device type that occur during the EP procedures in patients, users or other persons

    Time frame: During EP procedure

  2. Rate of Peri-procedural adverse device effects for each investigational device type

    Peri-procedural adverse device effects for each investigational device type that occur in all patients until or at the 24-hour follow-up

    Time frame: Until or at 24-hour follow-up

  3. Rate of Post-procedural adverse device effects

    Post-procedural adverse device effects that occur in the AlCath group after the 24-hour follow-up until or at the 3- to 6-month follow-up

    Time frame: After the 24-hour follow-up until or at the 3- to 6-month follow-up

  4. Percentage of Clinical benefit confirmations per number of use cases

    Clinical benefit at the time of procedure for each investigational device type

    Time frame: At the time of procedure

Other outcomes

  1. Procedure setting (related to used BIOTRONIK EP products and competitor products)

    Type of procedure, type of catheter models, recording system, RF ablation generator, irrigation pump, stimulator, 3D system, patient cable

    Time frame: Intervention

  2. Procedural parameters

    Fluoroscopy time, Procedure duration, duration of RF energy delivery, date and time of procedure

    Time frame: Intervention

  3. Patient details

    demographics, medical history, and concomitant cardiovascular medication

    Time frame: Baseline

  4. Device performance

    e.g., successful insertion and advancing of catheter, successful stimulation and recording of intracardiac signals, RF energy application, removal, replacement/substitution of catheter, device used within its intended purpose

    Time frame: Intervention

07

Study locations

1 of 1 sites recruiting
  • Immanuel Klinikum Bernau Herzzentrum Brandenburg
    Bernau bei Berlin, Brandenburg 16321, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Upon resonable request by authors or other scientifc reasons, but requires explicit approval by the sponsor.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will become available with uploading the results to clinical trial.gov. The data will be available as long as the study documents are archived.

Access criteria: On demand; in case of request by an author or in case of scientific reasons, but requires explicit approval by the sponsor.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jul 2030, 90 months after the start.

Of 69 industry-sponsored observational studies under Arrhythmias, Cardiac, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 90 months is above that.

Counting every sponsor, half of 259 studies reached it within 38 months; a quarter within 16 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Sep 30, 2022
StartActual
Jan 16, 2023
Primary completionEst.
Jul 2030
CompletionEst.
Jul 2030
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05560958
Responsible party
Sponsor
First posted
Sep 30, 2022
Start date
Jan 16, 2023
Primary completion
Jul 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Sep 8, 2026

Study contacts

Annette Thiem, Dr.
Contact
annette.thiem@biotronik.com
+49 (0) 151 6890 ext. 1303

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion